Atherosclerotic heart disease and osteoporosis are both diseases of old age. Evidence is accumulating for a link between vascular and bone disease. Calci cation is a common feature of atherosclerotic plaques, and osteoporosis is associated with both atherosclerosis and vascular calci cation. However, the relationship of vascular calci cation to the pathogenesis of atherosclerosis remains incompletely understood. Hormone replacement therapy has bene cial effects in the prevention of both atherosclerosis and osteoporosis. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas the statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis. We have reviewed recent advances in the knowledge of the actions of bisphosphonates and statins at the cellular, molecular and end-organ levels in order to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bones. These studies suggest that the mechanism of actions of these two classes of drugs at the cellular level may not be mutually exclusive. There are some early clinical data to complement these ndings, suggesting that statins increase bone density and bisphosphonates may have a bene cial effect in vivo on plasma lipid levels and on the atherosclerotic process. Properly designed prospective studies that examine the effect of statins on bone density and fractures, as well as the effects of bisphosphonates on lipid pro les, atherosclerotic progression and cardiovascular morbidity and mortality are needed to de ne clearly the clinical effects and potential new roles for these agents.
Introduction
Cardiovascular disease and osteoporosis together account for signi¢cant morbidity and mortality in the western world. Cardiovascular disease accounts for about 40% of deaths (*250 000 annually) in the UK. Osteoporosis is the most common metabolic bone disease and is clinically manifest as fractures, with hip fracture carrying the greatest morbidity and mortality. Estimates of the life-time risk from Europe range from 10 to 15% in women at age 50 years, with the risks in men being one-third to one-half of these values. 1 Evidence is accumulating for a link between vascular and bone disease. The epidemiological correlation between cardiovascular disease and osteoporosis is independent of age. Calci¢cation is a common feature of atherosclerotic plaques. 2 Osteo-porosis is associated with atherosclerosis and vascular calci¢cation. 3 Moreover, a recent population-based longitudinal study demonstrated that progression of atherosclerotic calci¢cation is associated with bone loss in women during the menopause. 4 However, the relationship of vascular calci¢cation to the pathogenesis of atherosclerosis remains incompletely understood. 5 Hypercholesterolaemia is a major risk factor for atherosclerotic heart disease, and the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) e¡ectively lower plasma cholesterol and reduce coronary artery disease morbidity and mortality. The statins inhibit HMG-CoA reductase, the rate-determining step of cholesterol biosynthesis (see Fig. 1 ) and have been shown to decrease vascular calci¢cation in relation to the magnitude of their LDL reduction. 6 Statins appear to have pleiotrophic properties that complement their cholesterol-lowering e¡ects. 7, 8 Bisphosphonates are potent inhibitors of bone resorption and are widely used in the treatment of osteoporosis. Moreover, amino-bisphosphonates that have been shown to act at the cellular level by inhibiting enzymes`downstream' of HMG-CoA reductase in the mevalonate pathway in osteoclasts 9 may in£uence lipid and apolipoprotein concentrations in the circulation. 10 In vitro 11 and in vivo studies in rodents 11 and humans 12^15 suggest a potential role for statins in the therapeutic management of osteoporosis, as well as cardiovascular disease. The purpose of this article is to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bone.
Mechanism of action of bisphosphonates
The class of compounds known as the bisphosphonates are non-hydrolysable pyrophosphate analogues that bind avidly to bone mineral surfaces in vivo and inhibit osteoclast-mediated bone resorption. 16 Clinically, bisphosphonates are used in the treatment of disorders of bone metabolism, including Paget's disease, metastatic bone disease and tumourinduced hypercalcaemia, and postmenopausal osteoporosis.
The anti-resorptive potency of bisphosphonates is dependent upon the structure of the side chains to the carbon of the phosphate^carbon^phosphate (P i^CP i ) moiety (see Fig. 2 ). The R 1 side chain in£uences the a¤nity for bone mineral, whereas biological activity depends on the R 2 side chain. 17 The pharmacology of the bisphosphonates and the relation between their chemical structure and anti-resorptive potency has been the focus of recent reviews. 18, 19 Biochemical measurements can be used to assess bone formation and resorption. 20 High bone turnover correlates inversely with bone mass in cross-sectional studies and may predict a high rate of bone loss. 21 The combined measurement of bone markers and bone mass may be used in the assessment of fracture risk. The earliest detectable e¡ect of bisphosphonates on markers of bone remodelling is a reduction in the excretion of bone resorption markers, such as deoxypyridinoline and degradation products of collagen. 22 The level of bone formation markers, such as osteocalcin or bone-speci¢c alkaline phosphatase, is reduced later, consistent with general suppression of bone turnover due to coupling of resorption and formation. 22 The earlier reduction in resorption markers re£ects the fact that inhibition of resorption is the primary e¡ect of bisphosphonates on bone. With continuous treatment, the steady state of lower remodelling rates is reached between 3 and 6 months after the start of treatment and is maintained as long as treatment is continued. 22 Osteoclasts are the ultimate target of bisphosphonate action. The e¡ects of bisphosphonates can be either direct or indirect via cells that control osteoclast formation or activity. At the cellular level, bisphos -phonates inhibit bone resorption by one or a combination of the following mechanisms: 16 ¢rstly, inhibition of osteoclast formation /recruitment; secondly, inhibition of osteoclast activation; thirdly, inhibition of the activity of mature osteoclasts; and fourthly, reduction of osteoclast lifespan by induction of apoptosis. Moreover, bisphosphonates have also been shown to act on osteoblasts 23 and to inhibit macrophages 24, 25 and tumour cells. 23 Although bisphosphonates have been known to inhibit osteoclast action, it is only in recent years that the targets and molecular mechanisms responsible for bisphosphonate inhibition of osteoclastic bone resorption have become clear. Bisphosphonates can be grouped into two pharmacological classes^those that contain and those that lack a nitrogen group in their chemical structure^and possess distinct molecular mechanisms of action. 18, 19 To date, there is no evidence for receptor-mediated bisphosphonate action, but cellular uptake is needed for bisphosphonate action.
Bisphosphonates and cholesterol biosynthesis
It has been shown by Amin et al. 9 in murine J774 macrophages that the bisphosphonates incadronate and ibandronate decrease bone resorption by inhibiting squalene synthase in the mevalonate pathway. The substrate of this enzyme is farnesyl diphosphate, and as mentioned previously, bisphosphonates are pyrophosphate analogues. Other bisphosphonates (alendronate and pamidronate) are poor inhibitors of squalene synthase but potent inhibitors of sterol biosynthesis, in a cell free system, suggesting that these bisphosphonates may inhibit other enzymes in the synthesis of farnesyl diphosphate from mevalonate. 9 J774 macrophages, like osteoclasts, undergo apoptosis after treatment with bisphosphonates. 26 Furthermore, bisphosphonate-induced apoptosis in osteoclasts and J774 macrophages may occur by a similar mechanism, since there is a correlation between the structure^activity relationships of bisphosphonates for inhibition of protein prenylation and induction of J774 macrophage apoptosis in vitro 27 and for inhibition of bone resorption in vivo. 24 As demonstrated by Luckman et al., 24 mevastatin, an inhibitor of HMG-CoA reductase, also causes apoptosis in J774 macrophages. In addition, the mevastatin-induced apoptosis is prevented by addition of mevalonate or the compounds farnesyl diphosphate or geranylgeranyl diphosphate. Interestingly, alendronate inhibition of osteoclast formation in culture is also reversed by mevalonate, suggesting a similar action to mevastatin, possibly inhibition of farnesyl diphosphate synthase alone. The involvement of enzymes of the mevalonate pathway in osteoclast activity is postulated to be via prenylation of guanosine triphosphate-binding proteins, including Ras, that regulate cytoskeletal arrangement. 24 This ability to inhibit farnesyl diphosphate synthase in vitro, protein prenylation in vitro and bone resorption in vivo has recently been con¢rmed with a wider range of nitrogen-containing bisphosphonate s, including zoledronate and minodronate. 28 Taken together, nitrogen-containing bisphosphonates (the most potent class) inhibit osteoclastmediated bone resorption by inhibiting farnesyl diphosphate synthase, thus preventing protein prenylation in osteoclasts. In contrast, bisphosphonates lacking nitrogen in their chemical structure do not inhibit protein prenylation and have a di¡erent mode of action that may involve the formation of cytotoxic metabolites or inhibition of protein tyrosine phosphatases.
Bisphosphonates have been shown to inhibit the development of experimental atherosclerosis in animals. Furthermore, bisphosphonates have been shown to accumulate in human arteries, and clodronate and pamidronate reduce arterial contractile force to a-adrenergic and depolariz ing stimuli. 29 Unexpected e¡ects on lipid and lipoprotein metabolism were found with chronic intravenous therapy (2-monthly) with neridronate in postmenopausal women with osteoporosis. 10 Signi¢cant decreases in serum LDL cholesterol and apolipoprotein B (apoB) and increases in HDL cholesterol and apoA-I occurred. The HDL cholesterol concentration rose progressively to 16% above baseline over the 12 months of the study. Interestingly, similar ¢ndings were obtained in four postmenopausal women given high intravenous doses of pamidronate or alendronate, suggesting a class e¡ect. Cyclical etidronate (1-year duration) for osteopaenia associated with type 2 diabetes resulted in a decrease in carotid intimam edia thickness using B-mode ultrasonography, suggesting that bisphosphonate s may have an antiatherogenic action. 30
Mechanism of action of statins
Being an endoplasmic reticulum protein, HMG-CoA reductase catalyses the rate-determining, reductive de-acylation of HMG-CoA to mevalonate in cholesterol biosynthesis. 31 Cholesterol is one of the major constituents of biological membranes and lipoproteins. The HMG-CoA reductase inhibitors or statins are reversible competitive inhibitors of HMG-CoA reductase. 32 The currently available statins include lovastatin, pravastatin, £uvastatin, simvastatin and atorvastatin. Cerivastatin has recently been withdrawn from the market. Other statins including rosuvastatin and pitavastatin are currently being investigated for their clinical usefulness. Statins are potent LDLcholesterol-lowering agents (up to 60%) with lesser but still signi¢cant e¡ects on triglyceride (up to 45%) and increases in HDL cholesterol (up to 10%).
HMG-CoA reductase inhibitors lower plasma LDL cholesterol by one or a combination of the following mechanisms: 33 (a) enhanced catabolism by upregulation of hepatic LDL receptors; (b) production of an LDL particle that is a better ligand for the LDL receptor; or (c) reduced production of LDL apoB caused by either decreased secretion of LDL directly into the plasma or decreased conversion of VLDL to LDL. Decreased conversion may be caused by either reduced secretion of hepatic VLDL or increased removal of VLDL [and intermediate density lipoprotein (IDL)] from the plasma by up-regulated LDL receptors.
ApoB kinetic studies have demonstrated that HMG-CoA reductase inhibitors decrease LDL apoB production rates. 34 Furthermore, there is increasing evidence in both experimental animals and humans that HMG-CoA reductase inhibitors lower apoB concentrations by decreasing hepatic VLDL apoB secretion into plasma. 33 However, not all studies have been consistent with this concept. Although the HMG-CoA reductase inhibitors have similar chemical structures, they di¡er in their chemical derivation, solubility and pharmacokinetic behaviour. The di¡erences in lipophilicity re£ect the potential of these compounds to di¡use across cell membranes. For example, simvastatin is given as a prodrug (lactone) that is activated to the b-hydroxy acid form in the liver. In contrast, atorvastatin is synthesized as the open acid form, and it has been proposed that the greater e¤cacy of atorvastatin is a result of more prolonged inhibition of HMG-CoA reductase, an e¡ect related to its hepatic selectivity and longer duration of action in the liver. Therefore, the di¡erences in apoB secretion observed in vivo among reported studies may, in part, pertain to the type and dose of HMG-CoA reductase inhibitor administered.
There is increasing evidence to suggest that the HMG-CoA reductase inhibitors have other e¡ects on vascular cells, such as decreasing smooth muscle cell migration and proliferation, that may modulate atherogenesis, plaque rupture or thrombosis. 35 Furthermore, some of these e¡ects appear independent of cholesterol-lowering. 7, 8 Along with cholesterol, the mevalonate pathway produces many isoprenoid compounds that are critical for diverse cellular functions (see Fig. 1 ). These include dolichols required for glycoprotein synthesis and polyisoprenoid side chains for ubiquinone and haeme A, involved in electron transport. Furthermore, mevalonate-derived isoprenoid compounds are post-translationally incorporated into proteins in their native forms (prenylated). Thus, the sum of the pleiotrophic e¡ects of statins may, in part, relate to a reduction in the formation of prenylated proteins through the mevalonate pathway. 36 Statins have a role in immunosuppression, 37 and recent in vivo evidence for direct, cholesterol-independent, anti-in£ammatory and anti-atherosclerotic activities of statins has been reported. 37 
Statins and bone formation
In 1999, Mundy et al. 11 showed that the statins increased new bone formation in vitro and in rodents. These investigators were searching for small molecules that activated the promoter of the bone morphogenic protein 2 (BMP-2) gene. BMP-2 is a bone growth factor that enhances osteoblast di¡erentiation. By linking the BMP-2 promoter to a ¢re£y luciferase reporter gene they were able to screen rapidly more than 30 000 compounds from a natural products collection for their ability to stimulate osteoblast activity. Only one compound, lovastatin, was found to activate speci¢cally the BMP-2 promoter. Subsequent studies using simvastatin, mevastatin and £uvastatin showed similar e¡ects. In vitro, these statins (1 to 5 mmol/L) speci¢cally increased BMP-2 expression and BMP-2 protein in cultured murine or human osteoblasts. In vivo, lovastatin and simvastatin increased osteoblast proliferation and bone formation when injected subcutaneously over the skull bones of mice. Moreover, this increase was of similar magnitude to that seen after treatment with BMP-2 and ¢broblast growth factor-1 (FGF-1). Oral administration of simvastatin (1 to 10 mg/kg/day) to rats increased the trabecular bone volume and rate of bone formation, even in ovariectomized animals. Although the doses used may seem high, when extrapolated from humans to rats with respect to lipid-lowering, the e¡ect of statins on bone occur at doses similar to the lipid-lowering doses used in humans. 33 The mechanism whereby statins induce BMP-2 is unclear. Furthermore, the e¡ect of statins on BMP-2 expression does not appear to be a class e¡ect. Sugiyama et al. 38 found that compactin and simvastatin, but not pravastatin (presumably because of its decreased lipophilicity) induced BMP-2 expression in human osteosarcoma cells. Treatment with mevalonate completely inhibited the statin-mediated activation of the BMP-2 promoter. Garrett et al. 39 have shown that simvastatin, lovastatin, atorvastatin, £uvastatin and cerivastatin, but not pravastatin, stimulate osteoblast accumulation and di¡erentiation, and new bone formation in organ cultures of the skull bones of mice. The e¡ect of the statins on bone formation correlated closely with the e¡ects on BMP-2 transcription in cultured murine osteoblasts. In addition to increasing BMP-2 expression, pitavastatin has been shown to enhance osteocalcin expression by inhibition of Rho-associated kinase in primary cultured human osteoblasts. 40 Recent studies in MC3T3-E1 cells would suggest that simvastatin has anabolic e¡ects on bone through promotion of osteoblast di¡erentiation and mineralization. 41 In a case^control study, using information from six health maintenance organizations in the USA, Chan et al. 12 found that regular statin use during a 2-year period (928 cases versus 2747 controls) was associated with a more than 50% reduction in fracture risk in elderly women when compared with the risk for untreated patients or those taking non-statin lipidlowering agents. Meier et al. 13 conducted a large population-based, nested case^control analysis (3940 cases versus 23 379 controls) in subjects 50 years and over using the UK-based General Practice Research Database. Current statin use (statin prescription ¢lled within 30 days prior to fracture) was associated with a 45% reduction in fracture risk, present even after relatively short treatment exposure (*1 to 4 months). Current use of ¢brates or other lipid-loweri ng agents was not related to a signi¢cantly decreased bone fracture risk.Wang et al. 14 conducted a case^control study (1222 cases versus 4888 controls) using several large databases in New Jersey, USA. Statin use in the previous six months was associated with a 50% reduction in risk of hip fracture. The degree of risk reduction was proportional to the duration of statin use. No such relationships were observed with nonstatin lipid-loweri ng therapies. Chung et al. 15 found that in 69 diabetic subjects there was a signi¢cant increase in bone mineral density (BMD) of the femoral neck after 15 months treatment with statins, compared with normolipidaem ic controls.
These early studies showed a consistent association between statin use and reduced fracture risk. However, it must be noted that they were retrospective and observational and therefore do not establish a cause^e¡ect relationship. Although a number of potential confounders were corrected for, unknown confounders or biases may explain the observed study ¢ndings. In contrast to the aforementioned studies, Edwards et al., 42 studying 41 post-menopausal women, failed to support the ¢nding that oral statin use increased BMD. Similarly, Wada et al. 43 found a lack of correlation between statin use and BMD in patients with type 2 diabetes, a signi¢cant proportion of whom were taking pravastatin. Furthermore, a retrospective analysis of the 4S data showed no association between fracture rate and statin use. 44 A recent report by Reid et al. 45 found that there was no signi¢cant e¡ect of pravastatin treatment on fracture risk in patients with ischaemic heart disease. However, it should be noted that pravastatin failed to induce BMP-2 expression in human osteosarcoma cells, 38 which may relate in part to its inability to enter cells other than hepatocytes. These ¢ndings clearly suggest that a statin's ability to decrease cholesterol levels (liver target) is unrelated to its ability to increase BMD or reduce fractures (bone target). Thus, appropriately controlled clinical intervention trials are needed to establish this relationship.
The short-term and/or long-term e¡ects of the di¡erent statins on bone histomorphometry or markers of bone remodelling in serum and urine are only beginning to be determined. However, extrapolating from studies with bone-forming agents such as intermittent parathyroid hormone (PTH), 46 an increase in bone formation markers as well as bone resorption markers would be expected. The bene¢cial e¡ects of statins on bone would be a result of the improvement in bone balance in the remodelling process. In a short-term study (12 weeks) using £uvastatin 40 mg/day, Bjarnason et al. 47 showed no e¡ect on bone formation markers in post-menopausal women with mild hypercholesterolaemia. Stein et al. 48 showed a reduction in bone-speci¢c alkaline phosphatase with simvastatin (40 or 80 mg/day for 12 weeks), but this e¡ect was not observed with atorvastatin (20 or 40 mg/day) in hypercholesterolaemic subjects. In contrast, Chan et al. 49 found that simvastatin (20 mg/day for only 4 weeks) increased serum osteocalcin but had no e¡ect on bone-speci¢c alkaline phosphatase in hypercholesterolaemic, non-osteoporotic subjects. Clearly, further studies to examine the e¡ects of statin therapy on bone remodelling markers are needed and would help in elucidating the mechanism of their action on bone.
Clinical implications
Under physiological conditions, maintenance of skeletal mass is the result of a tightly coupled process of bone resorption and bone formation, and an imbalance between resorption and formation leads to bone loss. Restoring the balance between these two processes in osteoporosis is crucial to its pharmacological management. Although intermittent PTH therapy is currently being trialled, with encouraging results, 50,51 most current treatments do not increase bone formation. 39 Oestrogen replacement is considered a ¢rst-line treatment for osteoporosis in post-menopausal women, in part because it is a natural form of treatment and has been shown to have cardioprotective e¡ects. Indeed, the cardiovascular bene¢ts of oestrogen replacement may outweigh the bene¢cial outcomes for bone health. 52 In patients in whom cardiovascular endpoints are of primary concern, oestrogen replacement has been shown to be bene-¢cial in primary prevention, 53 although recent studies have raised doubts about its e¡ectiveness in secondary prevention. 54, 55 A benign side e¡ect of oestrogen replacement for cardiovascular disease prevention is its bone-protective action.
Although bisphosphonates are relatively safe drugs, without breast and uterine side e¡ects or the inconvenience of possible recurrence of menstruation associated with oestrogen therapy, they are not considered to have the cardiovascular advantages of oestrogen replacement. However, in view of recent ¢ndings suggesting bene¢cial e¡ects of bisphosphonates on cardiovascular risk factors and atherosclerotic disease progression, this equation may need to be changed, 10, 30, 56 particularly if the bene¢ts of bisphosphonates are of a similar magnitude to those of oestrogen replacement.
Statins are used both in primary 57 and especially secondary cardiovascular disease prevention. 58^60 If the bene¢cial e¡ects of statins on bone health are con¢rmed that would support this use of statins in patients with cardiovascular risk who are also known (or considered) to be at risk of osteoporotic fractures. Studies to date raise the possibility that the combination of a statin with a bisphosphonate may be e¡ective in treating and/or preventing cardiovascular disease and osteoporosis.
Conclusion
There is evidence for the e¡ects of statins on bone and bisphosphonates on lipid metabolism, both at the molecular and cellular levels, as well as at the organ level.Whether these are of a magnitude to be clinically signi¢cant remains to be determined. Properly designed prospective studies that examine the e¡ect of statins on bone density and fractures, as well as the e¡ects of bisphosphonates on lipid pro¢les, atherosclerotic progression and cardiovascular morbidity and mortality, are needed to determine clearly the clinical e¡ects and potential new roles for these agents.
